Johnson & Johnson
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Johnson & Johnson's revenues will grow 1.0% and EPS will increase 0.8%.
The average estimate for revenue is $16.76 billion. On the bottom line, the average EPS estimate is $1.29.
Last quarter, Johnson & Johnson booked revenue of $16.14 billion. GAAP reported sales were 0.2% lower than the prior-year quarter's $16.17 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.37. GAAP EPS of $1.41 for Q1 were 13% higher than the prior-year quarter's $1.25 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 69.5%, 100 basis points worse than the prior-year quarter. Operating margin was 28.3%, 10 basis points worse than the prior-year quarter. Net margin was 24.2%, 270 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $67.48 billion. The average EPS estimate is $5.13.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 13,566 members out of 14,051 rating the stock outperform, and 485 members rating it underperform. Among 3,340 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 3,274 give Johnson & Johnson a green thumbs-up, and 66 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Johnson & Johnson is outperform, with an average price target of $71.32.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Johnson & Johnson. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Johnson & Johnson to My Watchlist.
Seth Jayson owned shares of the following at the time of publication: Johnson & Johnson. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition
A double-whammy of bad news just might help encourage J&J to go back into acquisition mode.
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.